Skip to main content
SpringerLink
Log in

No significantly increased risk of AEs with bivalent HPV vaccine

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. AEFIs = adverse events following immunisation

  2. ICD-10 = International Classification of Diseases, Version 10

  3. A school-based programme was implemented into the Finnish national vaccination programme in November 2013, in which Cervarix administered in three doses (0, 2 and 6 months) to females aged 11−13 years and as a catch-up in females aged 14−15 years.

Reference

  • Skufca J, et al. The association of adverse events with bivalent human papilloma virus vaccination: a nationwide register-based cohort study in Finland. Vaccine : [8 pages], 13 Aug 2018. Available from: URL: http://dx.doi.org/10.1016/j.vaccine.2018.06.074

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

No significantly increased risk of AEs with bivalent HPV vaccine. Reactions Weekly 1718, 8 (2018). https://doi.org/10.1007/s40278-018-51352-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-018-51352-y

Search

Navigation